Mixed-type Early Gastric Cancer
Conditions
Keywords
Mixed-type Early Gastric Cancer, Non-curative Outcomes, Nomogram Model, Prognosis, Dual-center Retrospective Cohort
Brief summary
The goal of this dual-center study is to identify the most valuable predictive factors (MVPs) for non-curable mixed-type early gastric cancer (NC-MTEGC) and develop a nomogram scoring model to assist surgeons in formulating precise postoperative combined radiochemotherapy strategies in patients with mixed-type early gastric cancer (MTEGC) who have undergone radical surgical resection. The main question it aims to answer is: What are the most valuable predictive factors for NC-MTEGC, and can a nomogram scoring model developed based on these factors effectively assist in formulating precise postoperative combined radiochemotherapy strategies? Patients with MTEGC who have undergone radical surgical resection (including 160 in the training group, 151 in the internal validation set from the First Affiliated Hospital of Nanchang University, and 110 in the external test cohort from the Second Affiliated Hospital of Nanchang University) will be included in the study. The Least Absolute Shrinkage and Selection Operator (LASSO) algorithm will be used to assess key predictive indicators, a nomogram prediction model will be developed based on logistic regression, and an NC-MTEGC risk score model will be constructed. Meanwhile, the model's discriminatory ability, calibration, and clinical utility will be comprehensively validated across the three cohorts, with follow-up for relevant conditions.
Interventions
None listed
Sponsors
The First Affiliated Hospital of Nanchang University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Mixed-type early gastric cancer (MTEGC); 2. Receive a surgical procedure; 3. Complete preoperative data.
Exclusion criteria
1. Received neoadjuvant therapy; 2. History of gastrectomy; 3. Previous cancer or residual gastric cancer (GC); 4. Distant metastasis at diagnosis; 5. Incomplete preoperative data; 6. Undifferentiated MTEGC components; 7. Missing imaging data or refusal of follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of adverse postoperative prognosis in patients with mixed-type early gastric cancer | From enrollment to the end of treatment at 5 years | Evaluate the incidence of adverse postoperative prognosis in patients with mixed-type early gastric cancer via the Nomogram model scoring. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathological malignancy grade | Periprocedural | Grading criteria refer to clinical guidelines: High risk, Medium risk, Low risk. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Ulcer long diameter | Periprocedural | Measured and reported in millimeters (mm) |
| T stage | Periprocedural | Staging criteria refer to clinical guidelines |
| Gender | Baseline | Binary classification, divided into male and female |
| Lymph node metastasis detected by CT | From enrollment to the end of treatment at 5 years | The status of lymph node metastasis is divided into no lymph node metastasis (no tumor cell invasion of lymph nodes detected) and lymph node metastasis (the presence of tumor cell invasion of lymph nodes). |
| P53 expression level | Periprocedural | Measured and reported as a percentage (%) |
| Lesion location | Periprocedural | The lesion locations are classified as follows: Gastric Body, Gastric Antrum, Gastric Angle, Cardia, Pylorus, and Antrum-Body Junction. |
| CEA level | Baseline | Measured and reported in nanograms per milliliter (ng/mL) |
| Ki67 expression level | Periprocedural | Measured and reported as a percentage (%) |
| Tumor lesion long diameter | Periprocedural | Measured and reported in millimeters (mm) |
Countries
China
Outcome results
None listed